首页> 美国卫生研究院文献>PLoS Clinical Trials >Therapeutic Rescue of Misfolded Mutants: Validation of Primary High Throughput Screens for Identification of Pharmacoperone Drugs
【2h】

Therapeutic Rescue of Misfolded Mutants: Validation of Primary High Throughput Screens for Identification of Pharmacoperone Drugs

机译:错误折叠的突变体的治疗性抢救:验证高药效筛选的初筛以鉴定药典药物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundFunctional rescue of misfolded mutant receptors by small non-peptide molecules has been demonstrated. These small, target-specific molecules (pharmacological chaperones or “pharmacoperones”) serve as molecular templates, promote correct folding and allow otherwise misfolded mutants to pass the scrutiny of the cellular quality control system (QCS) and be expressed at the plasma membrane (PM) where they function similarly to wild type (WT) proteins. In the case of the gonadotropin releasing hormone receptor (GnRHR), drugs that rescue one mutant typically rescue many mutants, even if the mutations are located at distant sites (extracellular loops, intracellular loops, transmembrane helices). This increases the value of these drugs. These drugs are typically identified, post hoc, from “hits” in screens designed to detect antagonists or agonists. The therapeutic utility of pharmacoperones has been limited due to the absence of screens that enable identification of pharmacoperones per se.
机译:背景技术已经证明了通过小的非肽分子对错误折叠的突变受体的功能性拯救。这些小的靶标特异性分子(药理伴侣或药理伴侣)可作为分子模板,促进正确折叠并允许错误折叠的突变体通过细胞质量控制系统(QCS)的审查,并在质膜(PM)上表达),其功能类似于野生型(WT)蛋白质。就促性腺激素释放激素受体(GnRHR)而言,即使一个突变位于遥远的位置(细胞外环,细胞内环,跨膜螺旋),拯救一个突变体的药物也通常可以拯救许多突变体。这增加了这些药物的价值。通常在事后从旨在检测拮抗剂或激动剂的筛选中的“命中”中识别出这些药物。由于不存在能够鉴定药物紫罗兰酮本身的筛选,因此药物紫罗兰酮的治疗用途受到限制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号